drugset / Trial / NCT00040469
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Phase 2
Terminated
15 enrolled
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine · collabThe Methodist Hospital Research Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
Timeline
- Start
- 2000-08
- Primary completion
- 2003-11-21
- Completion
- 2003-11-21
Outcome
Outcome not reported
Stopped (Enrollment): “accrual was slow and sporadic so the study was closed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Alemtuzumab | Monoclonal antibody | — | — |
| Background | Busulfan | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Phenytoin | Unknown | — | — |